Latest HAART Stories
Researchers have used radioimmunotherapy (RIT) to destroy remaining human immunodeficiency virus (HIV)-infected cells in the blood samples of patients treated with antiretroviral therapy, offering the promise of a strategy for curing HIV infection.
Overall death rates due to human immunodeficiency virus (HIV) infection declined over time between 1993 and 2007 for most men and women by race/ethnicity and educational levels, with the largest absolute decreases for nonwhites, but rates remain high among blacks.
Between 2000 and 2008, the proportion of HIV-infected patients in the U.S. receiving effective treatment known as highly active antiretroviral therapy (HAART) increased, and HIV-infected patients appeared to be less infectious and have healthier immune systems at death.
Researchers from Boston University School of Medicine (BUSM) and Fenway Health have found that highly active antiretroviral therapy (HAART) does not completely suppress HIV in the semen of sexually active HIV-infected men who have sex with men (MSM).
When the virus that causes AIDS infects the central nervous system, it can lead to the development of a severe neurological disease called HIV-associated dementia (HAD).
The Lancet, a leading global medical journal, published an editorial comment today that emphasizes the critical role of expanding access to HIV treatment under a "Treatment as Prevention" strategy to stop the HIV pandemic.
This observational cohort study, by Andrew Edmonds and colleagues, reports that treatment with highly active antiretroviral therapy (HAART) markedly improves the survival of HIV-infected children in Kinshasa, DRC, a resource-deprived setting.
The number of cancers and the types of cancers among people living with AIDS in the U.S. have changed dramatically during the 15-year period from 1991-2005.